TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16911750

Group type: EXPERIMENTAL
Intervention: Daily treatment (10 treatments, on business days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Spaced treatment (five treatments, on spaced business days)
Number of subjects: 16
Study: 11868063

Group type: EXPERIMENTAL
Intervention: Standard polarity (anterior pad = cathode) shocks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Reversed polarity (anterior pad = anode) shocks
Number of subjects: 110
Study: 9892586

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 4159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study: 8620173

Group type: EXPERIMENTAL
Intervention: Glucocorticosteroids (treated for 5-7 years)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (12 healthy persons)
Number of subjects: 46
Study: 2126741

Group type: EXPERIMENTAL
Intervention: Hydrophilic NTG oral spray (0.8 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lipophilic NTG oral spray (0.8 mg)
Number of subjects: 20
Study: 6989433

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (12-minute walk and stair climbing exercises, supervised once a week)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Supervised exercise training and Control group
Number of subjects: 33
Study: 31704264

Group type: EXPERIMENTAL
Intervention: Single UM171-expanded cord blood transplantation
Number of subjects: 22
Study: 31826005

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 416

Group type: COMPARATOR
Intervention: E/C/F/TDF
Number of subjects: 416
Study: 28060837

Group type: EXPERIMENTAL
Intervention: CSL‐111 (reconstituted HDL) 40 mg/kg, administered as 4 weekly intravenous infusions
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CSL‐111 (reconstituted HDL)
Number of subjects: 33
Study: 25640884

Group type: EXPERIMENTAL
Intervention: Navigator assistance for cancer screening (experimental condition, n = 242)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Cancer education (control condition, n = 246)
Number of subjects: 488
Study: 24096219

Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine + 25μg of fentanyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.25% bupivacaine + 25μg of fentanyl
Number of subjects: 40
Study: 21336617

Group type: COMPARATOR
Intervention: Dronedarone 400 mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19586828

Group type: EXPERIMENTAL
Intervention: 1 mg/mL morphine and 10 microg/mL nalbuphine (1:100)
Number of subjects: 174

Group type: COMPARATOR
Intervention: 1 mg/mL morphine
Number of subjects: 174
Study: 17524152

Group type: EXPERIMENTAL
Intervention: Heart surgery (coronary artery bypass surgery)
Number of subjects: 0
Study: 15129827

Group type: EXPERIMENTAL
Intervention: Group 1 (09:00 h after sleep)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Group 2 (12 h later)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 11210399

Group type: EXPERIMENTAL
Intervention: Carbatrol (200 mg) with a high-fat meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carbatrol (200 mg) fasted
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carbatrol (200 mg) sprinkled over applesauce (but otherwise fasted)
Number of subjects: 12
Study: 9558184

Group type: EXPERIMENTAL
Intervention: Verbal education + NSAID information sheet
Number of subjects: 56

Group type: COMPARATOR
Intervention: Verbal education only
Number of subjects: 56
Study: 7542052

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (200 mg/day for 4 weeks or individualized dosing for 6 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (3-4 weeks)
Number of subjects: 14
Study: 2377588

Group type: EXPERIMENTAL
Intervention: Breast self-examination training plus maintenance
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Breast self-examination training alone
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Breast self-examination maintenance
Number of subjects: 637

Group type: COMPARATOR
Intervention: Control (full measurement)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Low-measurement control
Number of subjects: 637
Study: 356970

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (DTIC 250 mg/m2 iv, Days 1-5; actinomycin D 0.5 mg/day iv, Days 1-5; methanol extracted residue of bacillus Calmette-Guérin 0.5 mg intradermally every 5 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Chemotherapy alone (DTIC 250 mg/m2 iv, Days 1-5; actinomycin D 0.5 mg/day iv, Days 1-5)
Number of subjects: 28
Study: 30010195

Group type: EXPERIMENTAL
Intervention: Paced breathing at 0.1 Hz (with cover story)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Paced breathing at 0.1 Hz (without cover story)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Paced breathing at 0.1 Hz (both groups)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Paced breathing at 0.28 Hz (control)
Number of subjects: 83
Study: 26070922

Group type: EXPERIMENTAL
Intervention: Structured telephone call
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Structured text message
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no post-procedure communication)
Number of subjects: 84
Study: 24793004

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 26
Study: 22652211

Group type: EXPERIMENTAL
Intervention: GIC (glass ionomer cement)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GSGIC (10% grape seed extract and GIC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CPPGIC (10% casein phosphopeptide-amorphous calcium phosphate and GIC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (lingual half of teeth)
Number of subjects: 45
Study: 20445533

Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of benazepril and valsartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (single-agent treatment with benazepril or valsartan)
Number of subjects: 0
Study: 18349171

Group type: EXPERIMENTAL
Intervention: Beta-blockers (specific mention of metoprolol and other beta-blockers)
Number of subjects: 2176

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2176
Study: 16045848

Group type: EXPERIMENTAL
Intervention: Steroid injections
Number of subjects: 82

Group type: COMPARATOR
Intervention: Footwear modification with orthoses
Number of subjects: 82
Study: 12942393

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: Candida parapsilosis fungemia
Number of subjects: 1591

Group type: COMPARATOR
Intervention: Observational cohort
Number of subjects: 1591
Study: 10574592

Group type: EXPERIMENTAL
Intervention: Overall haemostatic potential in plasma (OHPP) measured by ABS-sum
Number of subjects: 30
Study: 8706442

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (varying dosages)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol in combination with laminaria or tamoxifen
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 58
Study: 8993489

Group type: EXPERIMENTAL
Intervention: tacrine
Number of subjects: 73

Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 73
Study: 6193962

Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia
Number of subjects: 27
Study: 3865687

Group type: EXPERIMENTAL
Intervention: PGE2 (100-500 micrograms ml-1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PGF2 alpha (0.1-100 micrograms ml-1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Acetylcholine (0.1-50 mg ml-1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Citric acid (5-20% w/v)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PGF2 alpha and PGE2
Number of subjects: 15
Study: 31492716

Group type: EXPERIMENTAL
Intervention: IV glucose infusion (10% glucose at 410 mL/h)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oral glucose supplementation (2% concentration soft drink)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo (soft drink with aspartame, acesulfame-K)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 3
Study: 29863462

Group type: EXPERIMENTAL
Intervention: Mild-gain amplification for 4 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 26768929

Group type: EXPERIMENTAL
Intervention: 3mg/kg 0.5% prilocaine + 2 mL (100mg) tramadol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 3mg/kg 0.5% prilocaine + 2 mL (8 mg) lornoxicam
Number of subjects: 51

Group type: COMPARATOR
Intervention: 3mg/kg 0.5% prilocaine
Number of subjects: 51
Study: 24657033

Group type: EXPERIMENTAL
Intervention: N-acetylcystein 150 mg/kg followed by 50 mg/kg for 6 hours in 0.9% saline
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: N-acetylcystein
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 70
Study: 22782476

Group type: EXPERIMENTAL
Intervention: Advocate® (imidacloprid 10%/moxidectin 1%)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 36
Study: 20490567

Group type: EXPERIMENTAL
Intervention: Ultrapro mesh
Number of subjects: 402

Group type: COMPARATOR
Intervention: Prolene mesh
Number of subjects: 402
Study: 18064525

Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2 l/min oxygen via nasal prongs
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 6 l/min oxygen through a rebreathing face mask
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxygen as needed to achieve an arterial oxygen pressure (arterial pO(2)) of 200 mmHg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oxygen as needed to achieve an arterial oxygen pressure (arterial pO(2)) of 300 mmHg
Number of subjects: 14
Study: 15921933

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Glycopyrrolate (Control)
Number of subjects: 9
Study: 14519089

Group type: EXPERIMENTAL
Intervention: Oral GP IIb/IIIa inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous GP IIb/IIIa receptor blockers
Number of subjects: 0
Study: 12862143

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 113

Group type: COMPARATOR
Intervention: 1000 mg paracetamol
Number of subjects: 113
Study: 8873736

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 1891788

Group type: EXPERIMENTAL
Intervention: WBC-reduced platelet concentrates (PCs) and red cells (RBCs) with fewer than 10(6) WBCs per unit
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard blood components with a mean of 0.1 x 10(9) WBCs (PCs) and 1 x 10(9) WBCs (RBCs) per unit
Number of subjects: 31
Study: 6743481

Group type: EXPERIMENTAL
Intervention: Cimetidine 600 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31439299

Group type: EXPERIMENTAL
Intervention: Ablation including pulmonary vein isolation (PVI)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Ablation excluding pulmonary vein isolation (non-PVI)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Ablation including PVI
Number of subjects: 610
Study: 28881355

Group type: EXPERIMENTAL
Intervention: Weight Loss Intervention (WLI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 27646850

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control (no fibrin glue)
Number of subjects: 157
Study: 24717711

Group type: EXPERIMENTAL
Intervention: APF-30
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: APF-15
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: APF-0
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: APF-cotton
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no fluoride therapy)
Number of subjects: 25
Study: 22307566

Group type: EXPERIMENTAL
Intervention: Mixed soy isoflavones (PTIG-2535), 6-month intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo, 6-month intervention
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 19166770

Group type: EXPERIMENTAL
Intervention: Apical patency maintained during shaping procedures with a #10 K‐file (n = 115)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Apical patency maintained
Number of subjects: 300

Group type: COMPARATOR
Intervention: Apical patency not maintained (n = 121)
Number of subjects: 300
Study: 17454195

Group type: EXPERIMENTAL
Intervention: GnRH‐analog (GnRH‐a)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Chemotherapy (CHT) without GnRH‐a
Number of subjects: 29
Study: 15164912

Group type: EXPERIMENTAL
Intervention: Pictorial sleepiness scale based on cartoon faces
Number of subjects: 835
Study: 12215327

Group type: EXPERIMENTAL
Intervention: HP-hMG
Number of subjects: 781

Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 781
Study: 10100275

Group type: EXPERIMENTAL
Intervention: Serum ICAM-1 levels in patients with ALL
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Serum ICAM-1 levels in patients with Hodgkin's disease (HD)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Serum ICAM-1 levels in patients with acute myeloid leukemia (AML)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Serum ICAM-1 levels in patients with non-Hodgkin's lymphoma (NHL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Serum ICAM-1 levels in patients with Burkitt's lymphoma (BL)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Serum ICAM-1 levels in ALL patients in complete remission
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Serum ICAM-1 levels in HD patients in complete remission
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Correlation of serum ICAM-1 levels with high ESR in HD patients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High serum sICAM-1 levels
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Determination of serum level and/or tumor tissue expression of ICAM-1 in HD and ALL
Number of subjects: 54
Study: 8901350

Group type: EXPERIMENTAL
Intervention: Deaf
Number of subjects: 222

Group type: COMPARATOR
Intervention: Blind
Number of subjects: 222

Group type: COMPARATOR
Intervention: No sensory disability
Number of subjects: 222
Study: 2057991

Group type: EXPERIMENTAL
Intervention: Computer program predicting warfarin dosage adjustments
Number of subjects: 50

Group type: COMPARATOR
Intervention: Skilled professional care by an anticoagulation nurse-specialist
Number of subjects: 50
Study: 6144301

Group type: EXPERIMENTAL
Intervention: Oxmetidine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Smokers with healed ulcers
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Smokers with non-healed ulcers
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Increasing cigarette consumption
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Patients smoking nine cigarettes a day or less
Number of subjects: 83
Study: 30039182

Group type: EXPERIMENTAL
Intervention: real transcranial direct current stimulation (tDCS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 16
Study: 29304199

Group type: EXPERIMENTAL
Intervention: monovalent high‐dose type 2‐specific IPV (mIPV2HD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard trivalent IPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mIPV2HD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mOPV2
Number of subjects: 0
Study: 26620651

Group type: EXPERIMENTAL
Intervention: Football training group (FTG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study: 25675650

Group type: EXPERIMENTAL
Intervention: Uniform MDT (UMDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular MDT (RMDT)
Number of subjects: 0
Study: 23306000

Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg once daily)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Raltegravir (400 mg twice daily)
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 822

Group type: COMPARATOR
Intervention: Raltegravir
Number of subjects: 822
Study: 20940636

Group type: EXPERIMENTAL
Intervention: 10-second heavy resisted sprint on ice
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control condition (rest)
Number of subjects: 11
Study: 19058332

Group type: EXPERIMENTAL
Intervention: Antioxidant enteral supplement
Number of subjects: 21
Study: 16837793

Group type: EXPERIMENTAL
Intervention: rhGH therapy at the dose of 0.23 mg/kg/week s.c.
Number of subjects: 12
Study: 12802751

Group type: EXPERIMENTAL
Intervention: Oral pleconaril
Number of subjects: 1363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1363
Study: 10650298

Group type: EXPERIMENTAL
Intervention: Intensive 2-month exercise training program
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 9554153

Group type: EXPERIMENTAL
Intervention: Breast-feeding (at least once daily)
Number of subjects: 767

Group type: COMPARATOR
Intervention: Artificial feeding (control group)
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 767
Study: 1527286

Group type: EXPERIMENTAL
Intervention: Anistreplase (APSAC) 30 U/2 to 5 min with aspirin (160 mg/day) and intravenous heparin
Number of subjects: 325

Group type: COMPARATOR
Intervention: Alteplase (rt-PA) 100 mg/3 h with aspirin (160 mg/day) and intravenous heparin
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Anistreplase (APSAC)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Alteplase (rt-PA)
Number of subjects: 325
Study: 31948255

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention (daily exercises aimed at the foot arch)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 12
Study: 29800784

Group type: EXPERIMENTAL
Intervention: Amlodipine plus hydrochlorothiazide
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Amlodipine plus perindopril
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Perindopril plus hydrochlorothiazide
Number of subjects: 702
Study: 25884235

Group type: EXPERIMENTAL
Intervention: Ward-based psychological intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 51
Study: 24895806

Group type: EXPERIMENTAL
Intervention: HD-NBI
Number of subjects: 113

Group type: COMPARATOR
Intervention: HD-WL
Number of subjects: 113
Study: 22921291

Group type: EXPERIMENTAL
Intervention: Voice training group (n=14)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nontraining control group (n=34)
Number of subjects: 48
Study: 21084610

Group type: EXPERIMENTAL
Intervention: Activity in the parahippocampal cortex during encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity in several regions of the PFC and the hippocampus during encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rostrolateral PFC activity during encoding
Number of subjects: 0
Study: 18796517

Group type: EXPERIMENTAL
Intervention: Genistein aglycone (54 mg daily)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 16317127

Group type: EXPERIMENTAL
Intervention: High-iron rice (3.21 mg/kg Fe)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control rice (0.57 mg/kg Fe)
Number of subjects: 192
Study: 12866745

Group type: EXPERIMENTAL
Intervention: Penta E locus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Penta E, FGA, D18S51, D8S1179
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical parameters calculated
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall method
Number of subjects: 0
Study: 10390425

Group type: EXPERIMENTAL
Intervention: Proventil‐HFA (100, 200, and 400 micrograms)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ventolin‐CFC (100, 200, and 400 micrograms)
Number of subjects: 18
Study: 8893437

Group type: EXPERIMENTAL
Intervention: Biocompatible osteoconductive polymer
Number of subjects: 115

Group type: COMPARATOR
Intervention: Iliac bone graft
Number of subjects: 115
Study: 7961550

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 2958282

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (20 mg/2 ml)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 micrograms/2 ml)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Verapamil (5 mg/2 ml)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg in 4 ml) after placebo (4 ml saline)
Number of subjects: 15
Study: 30687806

Group type: EXPERIMENTAL
Intervention: Relaxing acupressure
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Stimulating acupressure
Number of subjects: 288

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Both acupressure groups (relaxing and stimulating)
Number of subjects: 288
Study: 27377675

Group type: EXPERIMENTAL
Intervention: 5-virus, lab-generated PCR panel
Number of subjects: 127

Group type: COMPARATOR
Intervention: FilmArray PCR panel
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 127
Study: 26881924

Group type: EXPERIMENTAL
Intervention: Pafuramidine (100 mg orally BID for 5 days)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Pentamidine (standard therapy for 7 days)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Pafuramidine (10 days)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Pentamidine (5 days)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Pafuramidine (5 days)
Number of subjects: 113